Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
Metrics: PDF 399 views | HTML 1794 views | ?
Chiara Citterio1, Michela Baccini2, Elena Orlandi1, Camilla Di Nunzio1 and Luigi Cavanna1
1Onco-Haematology Department, Hospital Guglielmo da Saliceto, 29121 Piacenza, Italy
2Department of Statistics, Informatics, Applications “G. Parenti”, Università di Firenze, 50134 Florence, Italy
Luigi Cavanna, email: email@example.com
Keywords: pancreatic cancer; second-line chemotherapy; oxaliplatin; irinotecan; gemcitabine based chemotherapy
Received: April 24, 2018 Accepted: June 04, 2018 Published: July 03, 2018
Guidelines for treatment of metastatic pancreatic cancer recommend a second line based on Fluoropyrimidine (FP) alone or in combination with Oxaliplatin (OXA) or Irinotecan (IRI) after a first line treatment based on Gemcitabine (GEM). We conducted a Bayesian network meta-analysis to compare currently available therapies to treat metastatic pancreatic cancer in the second line, considering as efficacy measures overall survival (OS) and progression free survival (PFS). Published randomized trials were identified using electronic databases (MEDLINE, PubMed, https://clinicaltrials.gov/ and American Society of clinical oncology). 8 studies met the inclusion criteria for a total of 1,587 patients and 7 different therapeutic schemes. The results suggested that the use of IRI-FP-Folinic Acid scheme in the second-line treatment of metastatic pancreatic cancer may offer a benefit in terms of OS and PFS for patients not previously treated with these drugs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.